.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average follow-up of 11 months, patients along with metastatic intestinal tumors that obtained biomarker-matched treatments based upon circulating lump DNA profiling presented a more significant professional benefit than those receiving incomparable therapy.